Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Stock Short Interest Report for September

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totaling 19,900 shares, a drop of 95.6% from the September 15th total of 451,633 shares. Based on an average daily volume of 1,643,901 shares, the days-to-cover ratio is presently 0.0 days. Currently, 7.2% of the company’s stock are short sold.

Scinai Immunotherapeutics Stock Down 2.5%

SCNI traded down $0.03 during trading on Friday, hitting $1.18. 19,238 shares of the company traded hands, compared to its average volume of 3,262,237. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.56 and a quick ratio of 1.35. Scinai Immunotherapeutics has a one year low of $1.06 and a one year high of $15.65. The stock’s fifty day moving average is $2.06 and its 200 day moving average is $3.57.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Scinai Immunotherapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday. One research analyst has rated the stock with a Sell rating. According to MarketBeat, the company has a consensus rating of “Sell”.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing immunotherapies for inflammatory and autoimmune diseases. The company’s research centers on NanoAb, its proprietary platform of single-domain antibodies designed to target disease-related proteins and potentially support localized treatment with reduced systemic exposure.

Scinai’s lead development program is SCNI-153, a NanoAb-based candidate targeting interleukin-17 (IL-17) for the treatment of plaque psoriasis.